- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
COA Responds to CMS Proposal to Ease Protections on 6 Drug Classes
Community Oncology Alliance (COA) responded to CMS' proposal to ease restrictions on how Medicare Part D and Medicare Advantage plans dictate access to 6 protected drug classes, calling the decision a potential nightmare for vulnerable patients with cancer.
Community Oncology Alliance (COA) responded to CMS' proposal to ease restrictions on how Medicare Part D and Medicare Advantage plans dictate access to 6 protected drug classes, calling the decision a potential nightmare for vulnerable patients with cancer. According to COA, for the first time ever, Medicare patients with cancer and other serious diseases will no longer have guaranteed access to potentially life-saving drugs and instead will have to go through step therapy and formulary restrictions.
Noting their support of the administration's efforts to lower drug prices, COA argues that weakening or dismantling protected classes of drugs is too far. Read the full press release from Jeff Vacirca, MD, FACP, president of COA.
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
